Study
| Multicenter, blinded, phase 2 study |
| Previously treated (platinum-containing therapy) patients with HER2m mNSCLC |
| Trastuzumab deruxtecan: 5.4 mg/kg (n=102) vs. 6.4 mg/kg (n=52) |
Efficacy
| ORR: 49.0% vs. 56.0 % |
| mDOR: 16.8 mos [6.4-NR] vs. NR [8.3-NR] |
| mPFS: 9.9 mos vs. 15.4 mos |
| 12 mos PFS: 45 % vs. 53% |
| mOS: 19.5 mos vs. NR |
| 12 mos OS: 67% vs. 73% |
Safety
| Grade≥3 AEs: Neutropenia (18.8% vs 36.0%), anemia (10.9% vs. 16.0%), fatigue (7.9% vs. 10.0%). |
Journal of Clin Oncol SEP, 2023
http://doi.org/10.1200/JCO.23.01361
Reviewed by Elvin Chalabiyev, MD on Sep 23, 2023
